1
|
Tomaselli PJ, Blake J, Polke JM, do Nascimento OJM, Reilly MM, Marques Júnior W, Laurá M. Intermediate conduction velocity in two cases of Charcot-Marie-Tooth disease type 1A. Eur J Neurol 2024; 31:e16199. [PMID: 38409938 DOI: 10.1111/ene.16199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/27/2023] [Accepted: 12/21/2023] [Indexed: 02/28/2024]
Abstract
BACKGROUND AND PURPOSE Charcot-Marie-Tooth disease type 1A (CMT1A) is the most prevalent hereditary neuropathy worldwide and classically has slow nerve conduction velocity (NCV), in most cases below 38 m/s. Two unrelated patients with motor NCVs in the upper limbs above 38 m/s are reported. METHOD Case report. RESULTS Two genetically confirmed CMT1A patients are presented, from two unrelated families (one of British origin and the other of Brazilian origin). Both individuals had upper limb motor NCVs above 38 m/s, with values ranging from 41.9 to 45 m/s in the median nerve and from 42 to 42.3 m/s in the ulnar nerve. They presented with a very mild phenotype, with CMT Neuropathy Score version 2 (CMTNSv2) of 6 and 5, respectively. In contrast, affected family members within both kinships exhibited a classical phenotype with more severe disease manifestation (CMTNSv2 ranging from 12 to 20) and motor NCVs below 30 m/s. CONCLUSION These cases, although very rare, highlight the importance of testing PMP22 duplication in patients with intermediate conduction velocities.
Collapse
Affiliation(s)
- Pedro José Tomaselli
- Clinical Hospital of Ribeirão Preto, Department of Neurosciences and Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil
| | - Julian Blake
- Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
- Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich, UK
| | - James M Polke
- UCLH Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, London, UK
| | | | - Mary M Reilly
- Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Wilson Marques Júnior
- Clinical Hospital of Ribeirão Preto, Department of Neurosciences and Behaviour Sciences, University of São Paulo, Ribeirão Preto, Brazil
| | - Matilde Laurá
- Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
| |
Collapse
|
2
|
Meyer AP, Forrest ME, Nicolau S, Wiszniewski W, Bland MP, Tsao CY, Antonellis A, Abreu NJ. Pathogenic missense variants altering codon 336 of GARS1 lead to divergent dominant phenotypes. Hum Mutat 2022; 43:869-876. [PMID: 35332613 PMCID: PMC9247498 DOI: 10.1002/humu.24372] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 03/18/2022] [Accepted: 03/22/2022] [Indexed: 01/03/2023]
Abstract
Heterozygosity for missense variants and small in-frame deletions in GARS1 has been reported in patients with a range of genetic neuropathies including Charcot-Marie-Tooth disease type 2D (CMT2D), distal hereditary motor neuropathy type V (dHMN-V), and infantile spinal muscular atrophy (iSMA). We identified two unrelated patients who are each heterozygous for a previously unreported missense variant modifying amino-acid position 336 in the catalytic domain of GARS1. One patient was a 20-year-old woman with iSMA, and the second was a 41-year-old man with CMT2D. Functional studies using yeast complementation assays support a loss-of-function effect for both variants; however, this did not reveal variable effects that might explain the phenotypic differences. These cases expand the mutational spectrum of GARS1-related disorders and demonstrate phenotypic variability based on the specific substitution at a single residue.
Collapse
Affiliation(s)
- Alayne P. Meyer
- Division of Genetic and Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA
| | - Megan E. Forrest
- Department of Human Genetics, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
| | - Stefan Nicolau
- The Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
| | - Wojciech Wiszniewski
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA
| | - Mary Pat Bland
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA
| | - Chang-Yong Tsao
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA
- Division of Child Neurology, Nationwide Children's Hospital, Columbus, Ohio, USA
- Department of Neurology, The Ohio State University College of Medicine, Columbus, Ohio, USA
| | - Anthony Antonellis
- Department of Human Genetics, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
- Department of Neurology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
| | - Nicolas J. Abreu
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA
- The Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
- Division of Child Neurology, Nationwide Children's Hospital, Columbus, Ohio, USA
| |
Collapse
|
3
|
Reilich P, Schlotter B, Montagnese F, Jordan B, Stock F, Schäff-Vogelsang M, Hotter B, Eger K, Diebold I, Erdmann H, Becker K, Schön U, Abicht A. Location matters - Genotype-phenotype correlation in LRSAM1 mutations associated with rare Charcot-Marie-Tooth neuropathy CMT2P. Neuromuscul Disord 2021; 31:123-133. [PMID: 33414056 DOI: 10.1016/j.nmd.2020.11.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 11/16/2020] [Accepted: 11/23/2020] [Indexed: 01/01/2023]
Abstract
More than 80 genes are known to be associated with Charcot-Marie-Tooth disease (CMT). Mutations of LRSAM1 were identified as a rare cause and define the subgroup of axonal neuropathy CMT2P. We identified additional 14 patients out of 12 families. Clinical and electrophysiological data confirm a late-onset axonal neuropathy with a predominance of sensorimotor impairment. The patients harbored ten different variants in LRSAM1, seven of which were novel. Due to variable inheritance patterns and clustering of pathogenic variants in 3´-prime exons, interpretation of genetic variants in LRSAM1 is challenging. The majority follows dominant inheritance, whereas recessive inheritance has been described for one variant. Variants at the 3`end may or may not escape from nonsense-mediated decay, thereby defining the pattern of inheritance. Our data emphasize the importance of the C-terminal RING domain, which exerts a dominant-negative effect on protein function, whenever affected by an altered or truncated protein. In conclusion, CMT2P is a rare, but nevertheless relevant cause of adult-onset axonal and painful neuropathy. ACMG (American College of Medical Genetics and genomics) criteria should be carefully applied in variant interpretation, with special attention to premature termination codon-introducing variants and their location within the gene.
Collapse
Affiliation(s)
- Peter Reilich
- Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Beate Schlotter
- Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Federica Montagnese
- Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Berit Jordan
- Department of Neurology, University Hospital of Halle, Halle, Germany; Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany
| | - Friedrich Stock
- Institute of Human Genetics, Universitätsklinikum Münster, Münster, Germany
| | | | - Benjamin Hotter
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Katherina Eger
- Gemeinschaftspraxis für Neurologie und Psychiatrie, Leipzig, Germany
| | - Isabel Diebold
- Department of Pediatrics, Technical University of Munich School of Medicine, Munich, Germany; Medical Genetics Centre, Bayerstr. 3-5, 80335 Munich, Germany
| | - Hannes Erdmann
- Medical Genetics Centre, Bayerstr. 3-5, 80335 Munich, Germany
| | - Kerstin Becker
- Medical Genetics Centre, Bayerstr. 3-5, 80335 Munich, Germany
| | - Ulrike Schön
- Medical Genetics Centre, Bayerstr. 3-5, 80335 Munich, Germany
| | - Angela Abicht
- Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany; Medical Genetics Centre, Bayerstr. 3-5, 80335 Munich, Germany.
| |
Collapse
|
4
|
Manganelli F, Pisciotta C, Reilly MM, Tozza S, Schenone A, Fabrizi GM, Cavallaro T, Vita G, Padua L, Gemignani F, Laurà M, Hughes RAC, Solari A, Pareyson D, Santoro L. Nerve conduction velocity in CMT1A: what else can we tell? Eur J Neurol 2016; 23:1566-71. [PMID: 27412484 DOI: 10.1111/ene.13079] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 06/09/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. METHODS Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot-Marie-Tooth Examination Score (CMTES). RESULTS NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. CONCLUSIONS This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.
Collapse
Affiliation(s)
- F Manganelli
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy.
| | - C Pisciotta
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy
| | - M M Reilly
- MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK
| | - S Tozza
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy
| | - A Schenone
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal Infantile Sciences, University of Genoa, Genoa, Italy
| | - G M Fabrizi
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - T Cavallaro
- Department of Neuroscience, AOUI, Verona, Italy
| | - G Vita
- Department of Clinical and Experimental Medicine, School of Neurosciences, University of Messina, Messina, Italy
| | - L Padua
- Department of Geriatrics, Neurosciences and Orthopaedics, Università Cattolica del Sacro Cuore, Rome, Italy.,Don Carlo Gnocchi Foundation, Milan, Italy
| | - F Gemignani
- Department of Neurosciences, University of Parma, Parma, Italy
| | - M Laurà
- MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK
| | - R A C Hughes
- MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK
| | - A Solari
- Carlo Besta Neurological Institute, IRCCS Foundation, Milan, Italy
| | - D Pareyson
- Carlo Besta Neurological Institute, IRCCS Foundation, Milan, Italy
| | - L Santoro
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy
| | | |
Collapse
|
5
|
Shen S, Benoy V, Bergman JA, Kalin JH, Frojuello M, Vistoli G, Haeck W, Van Den Bosch L, Kozikowski AP. Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease. ACS Chem Neurosci 2016; 7:240-58. [PMID: 26599234 DOI: 10.1021/acschemneuro.5b00286] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Charcot-Marie-Tooth (CMT) disease is a disorder of the peripheral nervous system where progressive degeneration of motor and sensory nerves leads to motor problems and sensory loss and for which no pharmacological treatment is available. Recently, it has been shown in a model for the axonal form of CMT that histone deacetylase 6 (HDAC6) can serve as a target for the development of a pharmacological therapy. Therefore, we aimed at developing new selective and activity-specific HDAC6 inhibitors with improved biochemical properties. By utilizing a bicyclic cap as the structural scaffold from which to build upon, we developed several analogues that showed improved potency compared to tubastatin A while maintaining excellent selectivity compared to HDAC1. Further screening in N2a cells examining both the acetylation of α-tubulin and histones narrowed down the library of compounds to three potent and selective HDAC6 inhibitors. In mutant HSPB1-expressing DRG neurons, serving as an in vitro model for CMT2, these inhibitors were able to restore the mitochondrial axonal transport deficits. Combining structure-based development of HDAC6 inhibitors, screening in N2a cells and in a neuronal model for CMT2F, and preliminary ADMET and pharmacokinetic profiles, resulted in the selection of compound 23d that possesses improved biochemical, functional, and druglike properties compared to tubastatin A.
Collapse
Affiliation(s)
- Sida Shen
- Drug
Discovery Program, University of Illinois at Chicago, 833 S. Wood
St., Chicago, Illinois 60612, United States
| | - Veronick Benoy
- Laboratory of Neurobiology, Vesalius Research Center (VIB) and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, O&N4 Herestraat 49, B-3000 Leuven, Belgium
| | - Joel A. Bergman
- Drug
Discovery Program, University of Illinois at Chicago, 833 S. Wood
St., Chicago, Illinois 60612, United States
| | - Jay H. Kalin
- Drug
Discovery Program, University of Illinois at Chicago, 833 S. Wood
St., Chicago, Illinois 60612, United States
| | - Mariana Frojuello
- Drug
Discovery Program, University of Illinois at Chicago, 833 S. Wood
St., Chicago, Illinois 60612, United States
| | - Giulio Vistoli
- Dipartimento
di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy
| | - Wanda Haeck
- Laboratory of Neurobiology, Vesalius Research Center (VIB) and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, O&N4 Herestraat 49, B-3000 Leuven, Belgium
| | - Ludo Van Den Bosch
- Laboratory of Neurobiology, Vesalius Research Center (VIB) and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, O&N4 Herestraat 49, B-3000 Leuven, Belgium
| | - Alan P. Kozikowski
- Drug
Discovery Program, University of Illinois at Chicago, 833 S. Wood
St., Chicago, Illinois 60612, United States
| |
Collapse
|